Evidence map›Paper›PMID 38180687›Full record

ArticleJournal of neuro-oncology2024

Treatment outcomes of single-fraction stereotactic radiosurgery for adenoid cystic carcinoma: a case series of 55 patients.

Sukwoo Hong, Yolanda I Garces, Katharine A Price, Yuki Shinya, Ian F Parney, Michael J Link, Bruce E Pollock

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sukwoo HongDepartment of Neurological Surgery, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, Minnesota, USA.
Yolanda I GarcesDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Katharine A PriceDivision of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Yuki ShinyaDepartment of Neurological Surgery, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, Minnesota, USA.
Ian F ParneyDepartment of Neurological Surgery, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, Minnesota, USA.
Michael J LinkDepartment of Neurological Surgery, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, Minnesota, USA.
Bruce E PollockDepartment of Neurological Surgery, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, Minnesota, USA. Pollock.Bruce@mayo.edu.
Mayo Clinic · USNeurological Surgery · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to analyze the treatment outcomes of single-fraction stereotactic radiosurgery (SRS) for adenoid cystic carcinoma patients.

methodsRetrospective analysis was conducted for 55 patients with 66 lesions. SRS intentions were categorized as definitive, adjuvant, salvage, and palliative. Tumor control was defined as local (within 50% isodose line), marginal (outside 50% isodose line), and distant (metastasis outside head/neck).

resultsThe median age was 60 years (range 21-85), with 53% males. Tumor origin was head/neck for 88% and trachea/lung for 12%. 61% were recurrent lesions. Median interval from diagnosis to SRS was 14 months. Preceding surgery was performed in 30%. SRS was administered as definitive (30 lesions), adjuvant (13), salvage (19), and palliative (4). SRS was used as a boost to external beam radiation therapy (EBRT) in 39%. Concurrent chemotherapy was administered in 26%. 5-, 10-, and 15-year local control rates were 60%, 33%, and 27%, respectively; local/marginal control rates were 29%, 13%, and 10%. For recurrent lesions treated with SRS without EBRT, 5-year local control rate was 14%, and local/marginal control rate was 5%. For recurrent lesions treated with SRS and EBRT, 5-year local control rate was 100%, and local/marginal control rate was 40%. The rate of distant failure after SRS was 40%. Older age and distant metastasis before SRS were negative factors for overall survival.

conclusionSRS provided a high rate of local tumor control, but marginal failure was frequent. Integrating SRS with added EBRT exhibits potential for enhancing local and local/marginal tumor control, particularly in recurrent cases.

Indexed as

Brain NeoplasmsCarcinoma, Adenoid CysticRadiosurgeryAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesTreatment OutcomeYoung AdultAdenocysticAdenoid cystic cancerCylindromaGamma knife

Identifiers

PMID38180687
OpenAlexW4390616064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.